Evaluating Melatonin as a Treatment to Protect the Heart in Adults With Cardiomyopathy

What this Trial Is About

Cardiomyopathy is a serious condition marked by abnormalities in the heart muscle that lead to poor heart function and other health problems. Despite current treatments like ACE inhibitors and beta-blockers, many patients continue to face a poor outlook. Researchers are studying melatonin, a hormone known for regulating sleep and having antioxidant and anti-inflammatory effects, to see if it can protect the heart in patients with cardiomyopathy by targeting key disease processes such as oxidative stress and mitochondrial dysfunction. In this study, participants will receive 10 mg of melatonin once daily alongside their usual cardiomyopathy treatment for three months. The study includes a comparison group receiving a placebo. This randomized, double-blind trial aims to evaluate the heart-protective effects of melatonin by monitoring blood pressure, heart rate, echocardiographic heart function, and blood markers over the treatment period. Participants will undergo regular assessments including blood pressure and heart rate measurements, echocardiograms, and blood tests for markers like NT Pro-BNP at the start and throughout the three months of treatment. Researchers will track these measures to evaluate melatonins impact on heart function and overall cardiovascular health. The study includes safety monitoring and follow-up throughout the treatment period, with total participation lasting about three months.

Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy